定义复制型病毒载体疫苗接种后不良事件监测间隔
本文讨论表达目标病原体异源抗原的活病毒载体疫苗(如HIV和埃博拉疫苗)在临床试验和流行病学研究中监测免疫后不良事件(AEFI)的适宜时间长度。文章提出四种可选策略:调整现行监管指南、专家小组系统文献回顾确定风险窗口、利用大型链接疫苗安全数据库进行近实时前瞻性监测(快速周期分析和Treescan),以及建立临床验证的预设特别关注不良事件(AESI)登记用于病例对照研究。具体选择取决于各国基础设施、人力资源和数据库条件,由监管机构和研究者决定。
要点
- 活重组病毒载体疫苗可能具有复制能力,需审慎定义AEFI监测时长。
- 确定监测间隔应基于临床前/临床数据、生物学合理性和实践可行性。
- 可采用调整指南、专家回顾、近实时数据库监测或AESI登记等策略。
核心结论
- 监测复制型病毒载体疫苗AEFI的适宜时间窗口需基于证据和可行性综合确定,可选多种策略。
研究设计与样本
- 本文为方法学讨论,未报告原始研究样本或系统检索范围。
主要发现
- 可用策略包括调整现行监管指南、专家小组系统文献回顾确定风险窗口、利用大型链接疫苗安全数据库进行近实时前瞻性监测(快速周期分析预设AESI和Treescan识别未知聚集),以及建立临床验证AESI登记用于病例对照研究。
关键数值与推荐
- 风险窗口可通过调整现行监管指南、专家回顾系统文献、近实时数据库监测或AESI登记等任一路径建立。
临床怎么用
- 监管机构和研究者可根据本国基础设施、人力资源和数据库条件选择单一或组合策略确定监测间隔。
局限性
- 未提供具体监测时长、风险窗口数值或各策略的验证数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Live viral vectors that express heterologous antigens of the target pathogen are being investigated in the development of novel vaccines against serious infectious agents like HIV and Ebola. As some live recombinant vectored vaccines may be replication-competent, a key challenge is defining the length of time for monitoring potential adverse events following immunization (AEFI) in clinical trials and epidemiologic studies. This time period must be chosen with care and based on considerations of pre-clinical and clinical trials data, biological plausibility and practical feasibility. The available options include: (1) adapting from the current relevant regulatory guidelines; (2) convening a panel of experts to review the evidence from a systematic literature search to narrow down a list of likely potential or known AEFI and establish the optimal risk window(s); and (3) conducting "near real-time" prospective monitoring for unknown clustering's of AEFI in validated large linked vaccine safety databases using Rapid Cycle Analysis for pre-specified adverse events of special interest (AESI) and Treescan to identify previously unsuspected outcomes. The risk window established by any of these options could be used along with (4) establishing a registry of clinically validated pre-specified AESI to include in case-control studies. Depending on the infrastructure, human resources and databases available in different countries, the appropriate option or combination of options can be determined by regulatory agencies and investigators.
引用
- Kochhar S, Excler JL, Bok K, et al. Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines. Vaccine. 2018. PMID: 30497831. doi:10.1016/j.vaccine.2018.08.085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。